AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17551159
Drug: Control (metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (metformin plus sulfonylurea)
Trial: 15167084
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.15 mg/kg b.i.d.
Trial: 15167084
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.30 mg/kg b.i.d.
Trial: 8169187
Drug: 5.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg caffeine
Trial: 3477659
Drug: Retinol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinol (15 mg or 50,000 IU), riboflavin (200 mg), and zinc (50 mg)
Trial: 28183047
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of an ellagitannin-containing pomegranate extract (PE) daily
Trial: 22832034
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 10 mg (6-11 years)
Trial: 22832034
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 40 mg (12-17 years)
Trial: 22832034
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 0.5 mg/kg (0-1 month)
Trial: 22832034
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (various doses)
Trial: 17392726
Drug: Naloxone 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.01 mg/kg
Trial: 12065339
Drug: Clarithromycin, 500
RxNorm normalized name: Clarithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 500 mg bid for 6 weeks
Trial: 9469367
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral granisetron (2 mg)
Trial: 9469367
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron (32 mg)
Trial: 7648772
Drug: Entacapone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (400 mg single dose)
Trial: 2652209
Drug: Systematic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic antibiotic prophylaxis for 48 h with sodium cefuroxim, 1.5 g the first dose and subsequent doses of 750 mg iv
Trial: 2652209
Drug: Selective antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective antibiotic prophylaxis based on determination of preoperative gastric pH (pH < 4, no antibiotic prophylaxis; pH > 4, prophylaxis as in group I)
Trial: 2652209
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy beginning postoperatively with cefuroxim 750 mg every 78 h for 4 days
Trial: 817696
Drug: Clonazepam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (3 to 6 mg daily) combined with previous antiepileptic drugs
Trial: 817696
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with previous antiepileptic drugs
Trial: 27119580
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro 200 U/mL (IL200)
Trial: 27119580
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro 100 U/mL (IL100)
Trial: 17481947
Drug: Optimal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal therapy for advanced chronic heart failure (specific intervention details not provided)
Trial: 7880791
Drug: Topical fusidic
RxNorm normalized name: fusidate Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fusidic acid gel (Fucithalmic)
Trial: 7880791
Drug: Oral oxytetracycline
RxNorm normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxytetracycline
Trial: 7880791
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fusidic acid gel and oxytetracycline
Trial: 2245455
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 mg twice a day)
Trial: 386974
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg propylthiouracil every two hours (group A)
Trial: 386974
Drug: 100 mg,
RxNorm normalized name: CoQmax Omega 100 mg, 500 mg-100 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, 100 mg, and 150 mg propylthiouracil at 8 hour intervals (group B)
Trial: 23514874
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with sevoflurane and fentanyl, and systemically administered opioids
Trial: 19144532
Drug: Ambroxol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (1000 mg/day by intravenous infusion on the day of operation and on the first 3 postoperative days)
Trial: 19144532
Drug: Fluid therapy
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid therapy only without ambroxol
Trial: 2681508
Drug: Cholestyramine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 12 g b.i.d.
Trial: 2681508
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg q.p.m.
Trial: 2681508
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Simvastatin + Cholestyramine)
Trial: 2681508
Drug: Simvastatin monotherapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin monotherapy after 52 weeks
Trial: 28410617
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (2 g/day for 3 months)
Trial: 24069844
Drug: Non-surgical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical therapy with EMD
Trial: 21739692
Drug: Acupoint catgut-embedding
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut-embedding combined western medicine (ACCWM)
Trial: 21739692
Drug: Simple western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple western medicine (WM)
Trial: 16714961
Drug: Brief focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief focal ultrasound followed by a 5-minute application of a 4% lidocaine topical anesthetic
Trial: 11323371
Drug: Diltiazem (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (10 mg)
Trial: 9293935
Drug: Intraoperative intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intermittent sequential compression (ISC)
Trial: 27199121
Drug: nebivolol (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol (5-20 mg/day)
Trial: 27199121
Drug: metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol succinate (100-300 mg/day)
Trial: 25701829
Drug: Nicorandil 10
RxNorm normalized name: nicorandil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 10 mg, 2 times a day (n = 27)
Trial: 19451137
Drug: COBRA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA combination therapy (step-down prednisolone, methotrexate, and sulfasalazine)
Trial: 19451137
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) monotherapy
Trial: 18193385
Drug: Teicoplanin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (800 mg on day 1, then 400 mg/day) + piperacillin/tazobactam + gentamicin
Trial: 18193385
Drug: Vancomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (2 g/day) + meropenem + levofloxacin
Trial: 17106142
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 mg, most frequent dose)
Trial: 17106142
Drug: ACEI (lisinopril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (lisinopril, enalapril, trandolapril)
Trial: 12612168
Drug: Protein supplements
RxNorm normalized name: PROTEIN SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplements with supplemental calcium
Trial: 8632120
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 10 mg
Trial: 8632120
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 25 mg
Trial: 8632120
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 50 mg
Trial: 8632120
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 100 mg
Trial: 1600852
Drug: Nilvadipine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (8 mg per day)
Trial: 1600852
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg per day)
Trial: 2866789
Drug: L-714,465 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-714,465 1% eyedrops
Trial: 22456954
Drug: Date palm
RxNorm normalized name: date palm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Date palm immunotherapy (IT) for 15 months
Trial: 18565853
Drug: Clofarabine plus
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine plus low-dose cytarabine
Trial: 15823640
Drug: switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switching to rosuvastatin 10 mg from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg
Trial: 15823640
Drug: switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switching to rosuvastatin 20 mg from atorvastatin 20 mg
Trial: 15823640
Drug: switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switching to rosuvastatin 10 mg from atorvastatin 20 mg
Trial: 12874270
Drug: Chemotherapy (etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (etoposide plus cisplatin) plus daily radiation therapy (RT)
Trial: 12874270
Drug: Chemotherapy (etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (etoposide plus cisplatin) plus split-course radiation therapy (RT) bid
Trial: 10381769
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg amphetamine
Trial: 9345413
Drug: Chimeric monoclonal
RxNorm normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric monoclonal anti-CD4 antibodies
Trial: 1879990
Drug: Netilmicin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin (5 mg/kg intramuscularly)
Trial: 1879990
Drug: Amikacin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (15 mg/kg intramuscularly)
Trial: 1879990
Drug: Fosfomycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (3 g per os)
Trial: 28657871
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg/day for 3 weeks, then 20 mg/day)
Trial: 28657871
Drug: tDCS (30-minute,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS (30-minute, 2-mA sessions for 15 weekdays, followed by 7 weekly treatments)
Trial: 28657871
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo)
Trial: 25819170
Drug: Doxapram injection
RxNorm normalized name: doxapram Injectable Solution
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxapram injection
Trial: 20032908
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injections with static night splint
Trial: 20032908
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injections without static night splint
Trial: 18396651
Drug: CEF-100 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48)
Trial: 18396651
Drug: CEF-60 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50)
Trial: 15297048
Drug: HPV18 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV18 L1 VLP vaccine
Trial: 28853210
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (as a reference)
Trial: 25641199
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl spray (INFS) 400 μg
Trial: 17330681
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg) plus methotrexate
Trial: 11929342
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400mg once daily for 7 days
Trial: 11929342
Drug: Cephalexin 500mg
RxNorm normalized name: CEPHALEXIN 500MG TAB
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500mg three times daily for 7 days
Trial: 30965392
Drug: Satavaptan (vasopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satavaptan (vasopressin V2 antagonist)
Trial: 28648618
Drug: H-s.c. (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-s.c. (subcutaneous trastuzumab)
Trial: 28648618
Drug: H-i.v. (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-i.v. (intravenous trastuzumab)
Trial: 17644057
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole 20mg o.d., levofloxacin 500 mg o.d., and amoxycillin 1g b.i.d. (4 tablets/day)
Trial: 17644057
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy comprising of rabeprazole 20mg, clarithromycin 500 mg, tinidazole 500 mg plus bovine lactoferrin 200mg (10 tablets/day)
Trial: 16372588
Drug: ACEI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI treatment for 4 weeks or more pre-operatively
Trial: 16372588
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ACEI treatment)
Trial: 2130825
Drug: tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets containing Mg citrate/Mg lactate 5 mmol three times a day
Trial: 2130825
Drug: tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets containing Mg citrate/Mg lactate and Mg hydroxide, 5 mmol three times a day
Trial: 2130825
Drug: tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets containing Mg hydroxide (Emgesan 10.3 mmol) twice a day
Trial: 2130825
Drug: solutions with
RxNorm normalized name: IV SOLUTIONS WITH ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solutions with Mg chloride (0.5 mmol/ml) 10 ml three times a day
Trial: 7000224
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids during or after operation (Wet)
Trial: 7000224
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fluids (Dry)
Trial: 31117236
Drug: Intracavernosal abobotulinumtoxinA
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intracavernosal abobotulinumtoxinA (Dysport®) 250 or 500 U as add-on therapy
Trial: 21140269
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (918 mg)
Trial: 17016059
Drug: Meloxicam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (7.5 mg cumulative dose)
Trial: 15288981
Drug: Capsule polishing
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule polishing
Trial: 2632753
Drug: Noradrenaline (subthreshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (subthreshold doses)
Trial: 30321318
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g force
Trial: 30321318
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g force
Trial: 26023212
Drug: lopinavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir monotherapy (arm A)
Trial: 22128296
Drug: FSH (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH (starting dose 50 IU for up to three treatment cycles)
Trial: 22128296
Drug: CC (50‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (50‐150 mg/day for 5 days)
Trial: 17897270
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (preoxygenation with 100% oxygen alone)
Trial: 11912385
Drug: Abarelix depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abarelix depot 100 mg
Trial: 11912385
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 7.5 mg plus bicalutamide 50 mg daily
Trial: 573763
Drug: Time-limited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-limited therapy
Trial: 573763
Drug: Time-unlimited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-unlimited therapy
Trial: 573763
Drug: Time-limited and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-limited and open-ended therapy (follow-up)
Trial: 31891407
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry juice concentrate (7.5 ml, 15 ml, 22.5 ml, or 30 ml twice daily for 28 days)
Trial: 29235560
Drug: Milk (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (1.5 g fat/100 mL)
Trial: 27686642
Drug: Fentanyl (0.001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.001 mg/kg)
Trial: 27686642
Drug: Dezocine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine (0.1 mg/kg)
Trial: 25424209
Drug: Diaper cream
RxNorm normalized name: CVS Zinc Oxide Diaper Cream
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaper cream applied twice daily (group II)
Trial: 25424209
Drug: Wet wipes
RxNorm normalized name: ALCOHOL 0.75 TOPICAL CLOTH [WET WIPES]
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet wipes and diaper cream applied twice daily (group III)
Trial: 12431929
Drug: Rectal Teaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Teaching Associate (RTA)
Trial: 7161138
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 70.0 mg ascorbic acid, 2.0 mg riboflavin, and 2.0 mg pyridoxine
Trial: 25915628
Drug: FRF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRF treatment at 67 °C for 3 seconds
Trial: 25915628
Drug: FRF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRF treatment at 62 °C
Trial: 25915628
Drug: FRF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRF treatment at 52 °C-57 °C
Trial: 25915628
Drug: FRF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRF treatment at 62 °C to 67 °C
Trial: 25531046
Drug: Aflibercept 6
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept 6 mg/kg plus docetaxel 75 mg/m²
Trial: 25531046
Drug: Aflibercept 4
RxNorm normalized name: aflibercept 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 4 mg/kg plus docetaxel 75 mg/m²
Trial: 22262486
Drug: Epoetin and
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin and oral ferrous sulfate
Trial: 11784739
Drug: Scopolamine (muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (muscarinic receptor antagonist)